Consensus CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-12 pm EDT			5-day change	1st Jan Change
5.600 ^USD	+37.59%		+25.56%	+64.22%

Jun. 12	Health Care Climbs Amid Deal Activity - Health Care Roundup	DJ
Jun. 12	Sector Update: Health Care Stocks Higher Late Afternoon	MT

Evolution of the Average Target: CureVac N.V.

Evolution of the Target Price: CureVac N.V.

Changes in Analyst Recommendations: CureVac N.V.

9.QNNPaMEO8QTJrgbLkZaL2TxtlHHn2CCN9I_lILi76Is.NYkHDvRKgEKPmHG-6Pr-r04-5AGjgk7YuuuAEefWpdkmuhU6g3ahZquaTw~50c424ecaa8ccc99ce4898f602e1d1ba

Analysts' recommendations: CureVac N.V.

CUREVAC : Successful cash burn reduction	Jun. 01
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating	Apr. 30	MT
CUREVAC : 2025 will be less costly	Apr. 11
CUREVAC : The mid-term effect of pipeline pruning	Feb. 21
CUREVAC : Licensing deal boosts bank account	Dec. 12
CUREVAC : Positive one-off overshadows pipeline dryness	Dec. 08
CUREVAC : Deutsche Bank reiterates its Neutral rating	24-09-02	ZD
CUREVAC : A beneficial deal	24-08-31
CUREVAC : Much noise at CureVac, overshadowing recent positive pipeline progress	24-08-20
CUREVAC : Significant cash drain in the Q1	24-05-23
CUREVAC : A missed opportunity	24-05-02
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	24-04-26	MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	24-04-25	MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	23-12-22	MT
CUREVAC : An untrimmed pipeline becomes costly	23-11-29
CUREVAC : Unchanged cash drain	23-11-28
CUREVAC : A missed opportunity	23-08-21
CUREVAC : Higher losses expected in future	23-07-25
CUREVAC : Some glimpse of positive pipeline developments	23-06-21
SVB Securities Initiates CureVac at Outperform With $13 Price Target	23-06-08	MT
CUREVAC : Runway prolonged	23-05-30
CUREVAC : One big point despite many misses	23-05-02
JMP Securities Adjusts Price Target on CureVac to $24 From $34, Maintains Outperform Rating	23-04-26	MT
CUREVAC : Everything hangs on the decision of the new CEO	23-03-16
UBS Upgrades CureVac to Buy From Neutral, Adjusts Price Target to $18 From $8	23-01-19	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	CUREVAC N.V.					+55.13%
	LONZA GROUP AG					+14.06%
	IQVIA HOLDINGS INC.					+19.71%
	CELLTRION, INC.					+32.48%
	EUROFINS SCIENTIFIC SE					-0.21%
	TEMPUS AI, INC.					-7.46%
	ICON PUBLIC LIMITED COMPANY					+21.98%
	MODERNA, INC.					+71.66%
	ASCENDIS PHARMA A/S					+31.2%
	QIAGEN N.V.					+5.64%
	Average					+24.42%
	Weighted average by Cap.					+20.11%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.544EUR

Average target price

5.608EUR

Spread / Average Target

+58.23%

High Price Target

10.59EUR

Spread / Highest target

+198.80%

Low Price Target

2.612EUR

Spread / Lowest Target

-26.30%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

alphavalue	Martin Schnee
UBS
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
Leerink Partners
Kempen
SVB Securities LLC
JMP Securities
Jefferies & Co.
BERENBERG	Zhiqiang Shu
Berenberg Bank
BofA Securities
Deutsche Bank Securities
Guggenheim